Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Telisotuzumab vedotin (ABBV-399), an antibody-drug conjugate (ADCs), targets c-Met and comprises the cytotoxic agent Monomethyl Auristatin E (MMAE), the Telisotuzumab antibody, and a cleavable mc-val-cit-PABC linker. This compound is utilized in cancer research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Telisotuzumab vedotin (ABBV-399), an antibody-drug conjugate (ADCs), targets c-Met and comprises the cytotoxic agent Monomethyl Auristatin E (MMAE), the Telisotuzumab antibody, and a cleavable mc-val-cit-PABC linker. This compound is utilized in cancer research [1]. |
Synonyms | ABBV-399 |
Molecular Weight | N/A |
CAS No. | 1714088-51-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Telisotuzumab vedotin 1714088-51-3 ABBV399 ABBV-399 ABBV 399 inhibitor inhibit